Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer

NCT07604766 is registered in ClinicalTrials.gov with Genmab as lead sponsor.

NCT NCT07604766
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07604766 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer
Lead sponsor
Genmab
Phase
Phase 3
Overall status
Recruiting
Start date
June 26, 2026
Completion date
December 31, 2028
Enrollment
82 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

platinum-resistant ovarian cancer